Caprelsa
What Caprelsa is used for
Caprelsa is indicated for the treatment of aggressive and symptomatic medullary thyroid cancer (MTC) in patients with unresectable locally advanced or metastatic disease. Caprelsa is indicated in adults, children and adolescents aged 5 years and older. For patients in whom re-arranged-during-transfection(RET) mutation is not known or is negative, a possible lower benefit should be taken into account before individual treatment decision.
Approved use, as published by the European Medicines Agency.
Key facts
- Brand
- Caprelsa
- Active substance
- vandetanib
- Disease area
- Thyroid Neoplasms
- Medicine group
- Antineoplastic and immunomodulating agents
- ATC code
- L01XE
- Marketing authorisation holder
- Esteve Pharmaceuticals, S.A.
- Authorised in the EU since
- 2012
Official information
In the USA
Same active substance: Caprelsa
In India
- Vandetanib: 1 brand in India
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Caprelsa used for?
Caprelsa is indicated for the treatment of aggressive and symptomatic medullary thyroid cancer (MTC) in patients with unresectable locally advanced or metastatic disease. Caprelsa is indicated in adults, children and adolescents aged 5 years and older. For patients in whom re-arranged-during-transfection(RET) mutation is not known or is negative, a possible lower benefit should be taken into account before individual treatment decision.
What is the active substance in Caprelsa?
Caprelsa contains vandetanib.
Who makes Caprelsa?
The EU marketing authorisation holder is Esteve Pharmaceuticals, S.A..
Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, EU